Phathom Pharmaceuticals, Inc. (PHAT) Financial Statements (2024 and earlier)

Company Profile

Business Address 100 CAMPUS DRIVE,
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments155,385,000183,259,000287,496,000243,765,000
Cash and cash equivalents155,385,000183,259,000287,496,000243,765,000
Inventory, net of allowances, customer advances and progress billings    
Inventory    
Other undisclosed current assets5,127,0003,267,0003,872,00011,836,000
Total current assets:160,512,000186,526,000291,368,000255,601,000
Noncurrent Assets
Operating lease, right-of-use asset2,287,0001,914,0002,373,000933,000
Property, plant and equipment1,207,000650,000986,000463,000
Other noncurrent assets299,000341,000384,000181,000
Other undisclosed noncurrent assets505,000   
Total noncurrent assets:4,298,0002,905,0003,743,0001,577,000
TOTAL ASSETS:164,810,000189,431,000295,111,000257,178,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24,675,00017,032,00027,700,0003,174,000
Interest and dividends payable477,000312,000156,000
Accounts payable9,997,0005,150,00016,782,000699,000
Accrued liabilities14,678,00011,405,00010,606,0002,319,000
Deferred revenue    
Debt   7,353,000161,000
Due to related parties35,0001,343,000173,000200,000
Other undisclosed current liabilities1,527,000546,00020,298,000213,000
Total current liabilities:26,237,00018,921,00055,524,0003,748,000
Noncurrent Liabilities
Long-term debt and lease obligation95,264,00090,854,00041,191,000635,000
Long-term debt, excluding current maturities95,264,00089,671,00039,634,000 
Liabilities, other than long-term debt8,598,0007,500,0004,125,0002,063,000
Deferred revenue    
Other liabilities7,500,0007,500,0004,125,0002,063,000
Operating lease, liability1,098,0001,183,0001,557,000635,000
Other undisclosed noncurrent liabilities 109,525,000  22,777,000
Total noncurrent liabilities:213,387,00098,354,00045,316,00025,475,000
Total liabilities:239,624,000117,275,000100,840,00029,223,000
Equity
Equity, attributable to parent(74,814,000)72,156,000194,271,000227,955,000
Common stock3,0003,0003,0002,000
Additional paid in capital652,276,000601,523,000579,755,000484,372,000
Accumulated deficit(727,093,000)(529,370,000)(385,487,000)(256,419,000)
Total equity:(74,814,000)72,156,000194,271,000227,955,000
TOTAL LIABILITIES AND EQUITY:164,810,000189,431,000295,111,000257,178,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(172,440,000)(135,080,000)(125,665,000)(106,215,000)
Operating loss:(172,440,000)(135,080,000)(125,665,000)(106,215,000)
Nonoperating expense(25,283,000)(8,803,000)(3,403,000)(148,916,000)
Investment income, nonoperating2,132,00041,0001,091,0001,089,000
Other nonoperating expense(110,000)(2,056,000)(8,000)(10,000)
Interest and debt expense(27,305,000)(6,788,000)(4,581,000)(4,177,000)
Loss from continuing operations:(225,028,000)(150,671,000)(133,649,000)(259,308,000)
Loss before gain (loss) on sale of properties:(150,671,000)(133,649,000)(259,308,000)
Other undisclosed net income27,305,0006,788,0004,581,0004,177,000
Net loss:(197,723,000)(143,883,000)(129,068,000)(255,131,000)
Other undisclosed net income attributable to parent    
Net loss available to common stockholders, diluted:(197,723,000)(143,883,000)(129,068,000)(255,131,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(197,723,000)(143,883,000)(129,068,000)(255,131,000)
Comprehensive loss, net of tax, attributable to parent:(197,723,000)(143,883,000)(129,068,000)(255,131,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: